AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02169258 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Systemic Strategy
Description: Significant CAD needing further revascularization is defined as patients who have luminal stenosis > 70% of the major epicardial vessels and bypass graft vessel or their major branches (> 50% for left main trunk or in-stent restenotic lesion) with reference vessel larger than 2.5 mm in diameter and moderate area of vulnerable myocardium for ischemia. Intermediate stenotic lesions should be determined if they are hemodynamic significant by fractional flow reserve (FFR) (\<=0.8). The choice of revascularization procedure, either percutaneous coronary intervention or coronary artery bypass surgery, depends on operator's or cardiovascular team's suggestion and patient's decision.
Study NCT02169258 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Strategy
Description: Significant CAD needing further revascularization is defined as patients who have luminal stenosis > 70% of the major epicardial vessels and bypass graft vessel or their major branches (> 50% for left main trunk or in-stent restenotic lesion) with reference vessel larger than 2.5 mm in diameter and moderate area of vulnerable myocardium for ischemia. Intermediate stenotic lesions should be determined if they are hemodynamic significant by fractional flow reserve (FFR) (\<=0.8). The choice of revascularization procedure, either percutaneous coronary intervention or coronary artery bypass surgery, depends on operator's or cardiovascular team's suggestion and patient's decision.
Study NCT03359395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfentanil
Description: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
Study NCT03359395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
Study NCT00561821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: one tablet daily
Study NCT00561821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: one tablet daily
Study NCT00561821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet daily
Study NCT03648372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: Intravenous infusion.
Study NCT02850406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: * Part A: Voxelotor will be administered as oral capsules or tablets~* Part B: Voxelotor will be administered as oral capsules or tablets~* Part C: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension~* Part D: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension
Study NCT01103349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: Double blind randomised parallel group study to assess efficacy and tolerability of BI 617800 in patients with symptomatic asthma
Study NCT04632342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL301 tablet 300mg
Description: * Experimental group 1 : 2 tablets at once, twice a day~* Experimental group 2 : 2 tablets at once, three times a day
Study NCT04632342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of HL301 tablet
Description: 2 tablets at once, three times a day
Study NCT01793454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fraction of inspired oxygen 40%
Study NCT01793454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fraction of inspired oxygen 80%
Study NCT01103349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo capsules and/or encapsulated tablets
Study NCT01103349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Double blind randomised parallel group study to assess efficacy and tolerability of BI 671800 in patients with symptomatic asthma
Study NCT02601885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-555
Description: Intravenous Infusion
Study NCT02601885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous Infusion
Study NCT00708994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: * Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~* Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~* Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.
Study NCT00708994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: • Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
Study NCT02717689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker based adjustment of corticosteroid dose
Description: The subject's corticosteroid dose will be adjusted based upon biomarker results (FeNO, eosinophils and periostin)
Study NCT01257451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: vildagliptin 50mg bid
Study NCT01257451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 50mg bid
Study NCT03271229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma (PRP)
Description: Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the antecubital vein.
Study NCT03509467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Information
Description: Personalized information about ways that participants can protect themselves and their child from developing melanoma.
Study NCT03509467 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Information
Description: Standard information about ways that participants can protect themselves and their child from developing melanoma.
Study NCT02651987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel 120 mg
Study NCT03509467 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DNA Extraction Determination of MC1R Genotypes
Description: After signing informed consent, a biologic sample (saliva) will be collected for the purpose of DNA extraction determination of MC1R genotypes. All participants who carry high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R variants will be randomized to the control or intervention arm.
Study NCT06076226 — intervention group
Intervention type: OTHER
Intervention: No intervention, observation study
Description: No intervention, observation study
Study NCT03768050 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advanced care for frail elderly
Description: Home-based case management group receives advanced nursing care meeting the health and social needs of patient and/or carer. It is carried out through a process of evaluation, planning\&coordination, facilitating the provision, monitoring and evaluation of the options and resources necessary for the resolution of the case. It is person-centred. The service also provides palliative care.~Home hospitalisation/early discharge dispenses medical and nursing care at home on a transient basis after hospitalisation when patients still need surveillance and assistance. It is done in the acute, subacute or post-acute phase. In the last phase the focus is on functional recovery.~The geriatric residences group is assisted by health care teams with expertise in geriatrics. They coordinate with primary care and health professionals of the residences to improve the attention. They are highly accessible, have high-resolutive capacity and can activate the resources of the healthcare network.
Study NCT02661347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
Study NCT01726803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Physical Therapy with Usual Care
Description: The early physical therapy arm includes 4 total sessions. The first 2 sessions include use of thrust spinal manipulation with exercises for range of motion and strengthening of the spine. The final 2 sessions include the exercise component only.
Study NCT02661347 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Risperidone
Description: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
Study NCT02661347 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which sub-threshold transcranial electric current (in the range of 0.4-2 mA) is applied via two conductive saline soaked electrodes placed on the scalp using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator.
Study NCT02661347 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which sub-threshold transcranial electric current (in the range of 0.4-2 mA) is applied via two conductive saline soaked electrodes placed on the scalp using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator.
Study NCT04245579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial Memory Training Program (UMAM method)
Study NCT03509467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DNA Extraction Determination of MC1R Genotypes
Description: After signing informed consent, a biologic sample (saliva) will be collected for the purpose of DNA extraction determination of MC1R genotypes. All participants who carry high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R variants will be randomized to the control or intervention arm.
Study NCT03015948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: a single dose of SHR4640 (n=8) for each dose cohort
Study NCT03015948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: a single dose of placebo (n=2) for each dose cohort .
Study NCT01395602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: cabergoline 0.5 mg twice weekly
Study NCT01395602 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 pill twice weekly
Study NCT04422834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: A group of students who studying at the Faculty of Health Sciences will be asked to fill the Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.
Study NCT03007693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will receive JNJ-61393215 for 7 days.
Study NCT03007693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive JNJ- 61393215 matching placebo for 7 days.
Study NCT04259970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Initiation of CFTR Modulator
Description: Inhaled contrast for MRI occurring at each 4 visits.
Study NCT01011881 — intervention group
Intervention type: OTHER
Intervention: pleural level of procalcitonin
Description: no intervention
Study NCT02754778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conditional workout
Description: 6 month of regular conditional workout 1-3 times a weak
Study NCT03195634 — intervention group
Intervention type: DRUG
Intervention: Carvedilol
Description: an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate >55 beats per minute, or up to 12.5 mg/day
Study NCT05002192 — intervention group
Intervention type: DRUG
Intervention: Eucalyptol, Limonene and Pinene Enteric Soft Capsule
Description: Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP_ONLY and EXP_ONLY cohort
Study NCT05002192 — intervention group
Intervention type: DRUG
Intervention: Ambroxol injection
Description: Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and cohort EXP+AMB Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort
Study NCT02913573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Pectoral nerve block is a regional block administered under ultrasound guidance which blocks the nerves of the thorax and chest areas.
Study NCT02913573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Description: Pectoral nerve block is a regional block administered under ultrasound guidance where 15 mL of 0.25% bupivacaine is instilled between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
Study NCT01726803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The usual care intervention includes advice and education to remain active and provision of the Back Book highlighting these recommendations. Pharmaceuticals may be prescribed at the discretion of the primary care provider. Follow-up visits to primary care provided are recommended for all patients dissatisfied with their progress.
Study NCT01726803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The usual care intervention includes advice and education to remain active and provision of the Back Book highlighting these recommendations. Pharmaceuticals may be prescribed at the discretion of the primary care provider. Follow-up visits to primary care provided are recommended for all patients dissatisfied with their progress.
Study NCT05002192 — intervention group
Intervention type: DRUG
Intervention: Other oral mucolytic drugs
Description: Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP_ONLY and EXP_ONLY cohort
Study NCT03819803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: 200 ml of a tested stool suspension of a healthy donor is instilled into the patient´s caecum or terminal ileum
Study NCT02045277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Lotion
Description: Lotion
Study NCT02045277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-118 Monad HP Lotion
Description: Active Comparator
Study NCT02045277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-118 Monad Taz Lotion
Description: Active Comparator
Study NCT02045277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-118 Vehicle Lotion
Description: Vehicle
Study NCT01703819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurexan®
Description: 0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
Study NCT01703819 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
Study NCT01040780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125 mg three times daily (375 mg per day) by mouth
Study NCT01040780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: 250 mg every 24 hours by mouth
Study NCT02955433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rideshare-based transportation
Study NCT00630253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: 30 mg/kg/day will be administered after MP on days -6, -5, -4, -3 and -2.
Study NCT02191917 — intervention group
Intervention type: PROCEDURE
Intervention: Respiratory muscle strength measurements by different techniques.
Study NCT02134314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 Esterase Inhibitor
Description: C1 Esterase Inhibitor 50 units per kilogram intravenous infusion administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
Study NCT00630253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.
Study NCT00630253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 35 mg/m\^2 intravenously (IV) on days -6 through -2.
Study NCT02134314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
Study NCT00630253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation
Description: Bone marrow or umbilical cord blood infusion on day 0.
Study NCT00630253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone (MP) 2 mg/kg/day intravenously every 24 hours will be given from day -6 until day -2 as a premedication for ATG.
Study NCT02906683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-303
Description: Oral administration for 8 weeks, once daily.
Study NCT02906683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration for 8 weeks, once daily.
Study NCT00859898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, once daily, 24 weeks
Study NCT00859898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablets, Oral, up to 2000 mg, once daily, 24 weeks
Study NCT00859898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks
Study NCT00630253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mcg/kg per day intravenously (IV) continue until Absolute neutrophil count > or = 2.5 x 10\^9/L
Study NCT00859898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin matching Placebo
Description: Tablets
Study NCT00630253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine IV over 2 hours or orally every 8-12 hours beginning on day -3 and continuing until day 100, followed by a taper.
Study NCT00630253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] > 0.5 x 10\^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours PO (to a maximum dose of 1 gram).
Study NCT01015963 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Perform DNA sample analysis
Study NCT02186353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial feeding study
Description: Provision of all grain foods where only the processing of kernels used to produce the grain foods will differ among test diets. Each participant will be assigned to complete the three 4-week test diets in random sequence.
Study NCT00859898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin HCl Modified Release matching Placebo
Description: Tablets
Study NCT01819922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: 600 mg as powder in capsule, one dose within 5 minutes prior to AM meal
Study NCT01819922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder in capsule, one dose within 5 minutes prior to AM meal
Study NCT03010423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: Participants received Nicorandil 5 milligram (mg) tablet, three times a day for 12 weeks.
Study NCT03048721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Tape Stripping
Description: For psoriasis group, tape-stripping will be done in both involved and uninvolved skin. The tape-stripping will be performed within 2.5 cm of the first punch biopsy. For healthy control group, tape-stripping will be performed on normal skin, within 2.5. cm of the first punch biopsy.
Study NCT03048721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch Biopsy
Description: For psoriasis group, one punch biopsy will be taken from each of the following areas: involved skin, tape-stripped involved skin, uninvolved skin, and tape-stripped uninvolved skin. For healthy control group, one punch biopsy will be taken from each of the following areas: normal skin and tape-stripped normal skin (within 2.5 cm of the first punch biopsy).